Bli medlem
Bli medlem

Du är här


IDL Biotech: Redeye: IDL Biotech - Showing progression in line with investment case

We provide a short research update with the latest financial estimates
and valuation following IDL Biotech's Q2'19 report. We factor in
higher gross margins and slightly lower costs related to SG&A in
near-term, which has a positive effect on our valuation. Our new base
case amounts to SEK 3.8 per share, with a Bull and Bear Case of SEK
7.4 and 1.5 per share, respectively.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.